Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524351 · ClinicalTrials.gov registry record · Phase 1
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
A Phase 1 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT04524351 is a Phase 1 study that has completed, run by Annovis Bio. The registered enrollment target is 75 participants.
The verdict
NCT04524351, a Phase 1 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study. In Part one of the study Investigators will recruit 14 AD and 14 PD patients who will either receive placebo (an inert pill which looks like the study drug) or the study drug Posiphen, both taken daily. In Part two of the study Investigators will recruit 40 PD patients who will receive different strengths of the study drug Posiphen taken daily. Patients will be required to come to the site for 3 face to face visits and have 4 phone calls, tests include but are not limited to, blood and CSF (spinal fluid) sampling, cognitive assessments, clinical examinations and laboratory safety tests. Primarily the Investigators are looking for the safety and tolerability of Posiphen, although Investigators will also evaluate the activity of Posiphen by a number of different biomarkers measuring pathway and target engagements.
Interventions
- DRUG Placebo
- DRUG Posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524351
The ClinicalTrials.gov registry entry for NCT04524351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04524351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524351 about?
NCT04524351 is a clinical study titled "Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients". Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study. In Part one of the study Investigators will recruit 14 AD and 14 PD patients ...
What is the current status of trial NCT04524351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2020-08-14. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04524351?
The interventions under investigation include: Placebo (DRUG), Posiphen (DRUG).
Who is sponsoring clinical trial NCT04524351?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.